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Stefan O. Ciurea,1 Victor Mulanovich,2 Ying Jiang,2 Roland Bassett,3 Gabriela Rondon,1
John McMannis,1 Marcos de Lima,1 Elizabeth J. Shpall,1 Richard E. Champlin1Alternative donor stem cell transplantation from cord blood or haploidentical peripheral blood donors is
increasingly being used for patients who lack a matched related or unrelated donor. A higher nonrelapse
mortality (NRM) rate has been noted with these 2 types of transplants, primarily because of infectious
complications. Here, we hypothesized that the time to lymphocyte recovery (absolute lymphocyte count
[ALC] of $1000/mL for the first 3 consecutive days) after transplant correlates with outcomes. We retro-
spectively analyzed 65 consecutive patients treated at our institution with cord blood (n 5 37) and haploi-
dentical (n 5 28) transplantation with myeloablative fludarabine, melphalan, and thiotepa conditioning.
Patients with lymphocyte recovery at day 60 posttransplant were more likely to survive long term than those
without lymphocyte recovery. In multivariate analysis, ALC recovery was the only independent prognostic
factor associated with mortality; patients without ALC recovery were 10.5 times (95% confidence interval
[CI]: 4.3-25.4) more likely to die than those with ALC recovery (P\.0001). This difference appeared to be
related to NRM (hazard ratio [HR] 5 0.1, 95% CI: 0.02-0.6, P 5 .008), whereas ALC recovery did not
influence the rate of disease relapse. These results suggest that ALC recovery is an important prognostic
indicator for patients treated with cord blood and T cell–depleted peripheral haploidentical transplants.
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haploidentical stem cell transplantationINTRODUCTION transplants. Impaired functional recovery of lympho-Transplantation using alternative sources of stem
cells, from mismatched relatives or umbilical cord
blood, is an established treatment modality for patients
who lack a matched sibling or unrelated donor [1,2].
The morbidity and mortality rates with these types
of transplant have been higher than those for
matched transplants because of a higher incidence
of infectious complications [3-8]. Delayed immuno-
logic reconstitution also likely contributes to the
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6/j.bbmt.2010.11.020cytes, in addition to prolonged lymphopenia, was
previously observed in both T cell–depleted haploi-
dentical and cord blood transplant recipients [9,10].
We and others have also found a higher nonrelapse
mortality (NRM) rate primarily related to infectious
complications, which was the predominant cause of
unfavorable outcomes in these patients [9,11].
Lymphocyte recovery has been previously corre-
lated with lower rates of disease relapse after autolo-
gous or allogeneic stem cell transplantation in
patients with hematologic malignancies, and faster
absolute lymphocyte count (ALC) recovery has been
found to be associated with lower rates of relapse
and improved survival [12-23]. Limited data exist on
the relationship between lymphocyte recovery and
outcomes in alternative donor transplants [24],
whereas no data exist for these 2 types of transplants.
Moreover, it is unclear whether delayed ALC recovery
contributes to higher treatment-related mortality
(TRM) and relapse rates in patients treated using alter-
native sources of stem cells.
Here, we hypothesized that ALC recovery may be
a useful predictor of outcomes in these patients, and
analyzed the relationship between ALC recovery and1169
1170 Biol Blood Marrow Transplant 17:1169-1175, 2011S. O. Ciurea et al.relapse, NRM, and survival in cord blood and T cell–
depleted haploidentical transplant recipients treated at
a single institution.PATIENTS AND METHODS
Patients
We searched the database of the Department of
Stem cell Transplantation and Cellular Therapy and
identified 65 consecutive patients who had received
a transplant, T cell–depleted haploidentical (n 5 28)
or cord blood (n 5 37) at The University of Texas
M.D. Anderson Cancer Center between 10/2001 and
5/2008. Patients were treated simultaneously on sepa-
rate protocols. Patients treated with a cord blood
transplant could have up to 10% bone marrow blasts
at the time of transplant, whereas no cutoff existed
for haploidentical transplant recipients. All patients
were treated on clinical trials approved by the institu-
tional review board (IRB) of M.D. Anderson, and pro-
vided written informed consent. An IRB-approved
protocol and a waiver of informed consent were
obtained for this retrospective study.
Conditioning Regimen
All patients were treated with a preparative regimen
consisting of melphalan at 140 mg/m2 8 days before
transplantation (day 28), thiotepa at 10 mg/kg on day
27, fludarabine at 160 mg/m2 in divided doses given
on days 26, 25, 24, and 23, and 6 rabbit antithymo-
cyte globulin (ATG) at 1.5 mg/kg/day on days26,25,
24, and 235. Cord blood transplant patients received
tacrolimus-based graft-versus-host disease (GVHD)
prophylaxis with either methotrexate (MTX) or myco-
phenolate mofetil (MMF), whereas haploidentical stem
cell transplant (HSCT)patientshadonlyTcell depletion
as GVHD prophylaxis. Patients developing GVHD
greater than grade 2 were routinely treated with steroids
(methylprednisolone 2 mg/kg in divided doses). All
treated patients received standard antimicrobial prophy-
laxis with voriconazole, valacyclovir, trimethoprim-
sulfamethoxazole, or pentamidine. Patients received
foscarnet prophylaxis for cytomegalovirus (CMV)
infection and gancyclovir only for treatment of CMV
antigenemia or disease.
Lymphocyte Recovery
Lymphocyte recovery was defined as the first day
of 3 consecutive days (or ALC values) in which the
ALC was $1000/mL, regardless of how long after
transplantation this occurred. A cutoff of 1000/mL
was chosen because a higher ALC variability was
observed with lower thresholds for ALC, which
made the interpretation of the results more difficult.
Patients who eventually experienced lymphocyterecovery had a general upward trend until they reached
this value. In addition to ALC recovery, other param-
eters such as neutrophil and platelet recovery, defined
in the usual fashion (first day of 3 consecutive days of
absolute neutrophil count above 500/mL, and platelet
count 20,000 for 7 consecutive days without platelet
transfusions), number of CD341 cells infused, and dis-
ease status at transplant (complete remission versus
not) were evaluated in relation to the following out-
comes: NRM, disease relapse, and survival. To avoid
a potential intrinsic selection bias, patients who did
not have the chance to recover the lymphocytes, such
as those who developed primary graft failure
(n 5 10) or who died before day 60 posttransplant
(n 5 3), were excluded from the analysis.Infectious Complications
We identified episodes of infection, documented
both clinically (signs and symptoms of infection, radio-
logic evidence, and no microorganism identified) and
microbiologically (signs and symptoms and microbio-
logic or pathologic identification of the etiologic
agent), and then determined the number of patient-
days from transplant to last follow-up or death. For
the group with ALC recovery, we also determined
the number of patient-days from transplant to ALC
recovery and from ALC recovery to last follow-up or
death and defined the infection rate as the number of
infection episodes per thousand patient-days.Statistical Analysis
Competing risk analysis was used to assess the com-
peting risks of relapse andNRM [25]. Cox proportional
hazards regression analysis was used to evaluate the
effects of transplant type and CD341 cell count on
the recoveries of different blood cells and to assess the
effects of certain prognostic factors on overall mortality
[26]. The prognostic factors tested included age, disease
status at transplantation, type of transplant, CD341 cell
count, ALC recovery, platelet recovery, and neutrophil
recovery. Of these, the recoveries of the different blood
cells were time-dependent variables in the Cox model
analysis. In addition, if ALC recovery was found to be
a significant factor in multivariate survival analyses,
a certain cutoff value was chosen and patients were
dichotomized based on it, and then the relevant survival
curves were estimated by theKaplan-Meiermethod and
compared using the log-rank test [27]. The incidence
rates of infectious complications were calculated and
compared by a normal-theory test using normal
approximation to the binomial distribution. Poisson
distribution and test-based methods were used to con-
struct the confidence intervals for incidence rate ratios.
All tests were 2-sided, and the statistical significancewas
set at P # .05. All statistical analyses were performed
Table 1. Patient Characteristics and Treatment Outcomes
Characteristics
No. of Patients
(N 5 65)
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and R (http://www.r-project.org) version 2.9.2 soft-
ware.Type of transplant
Haploidentical/cord blood 28/37
Age, years (range) 34 (4-57)
Sex
Male/female 40/25
Diagnosis
AML/MDS 29
ALL 20
NHL/HD 13
CML/MPD 2
CLL 1
Disease status at transplantation
Complete remission (%) 28 (43%)
Conditioning chemotherapy
FMT ± ATG 100%
GVHD prophylaxis
T cell depletion with no posttransplant
immunosuppression
28
Tacrolimus-based* 37
Number of CD34+ cells infused, median (106/kg)
Haploidentical SCT patients 10.5
Cord blood transplant patients 0.11RESULTS
Patient and Treatment Characteristics
The median age of the patients studied was 34
years (range: 4-57 years), 37.3 years for the haploident-
ical transplant group, and 29.3 years for the cord blood
group (P 5 .059, Wilcoxon rank sum test). Patients’
disease and treatment characteristics are listed in
Table 1. Forty-nine patients (75%) had acute leuke-
mia, and 13 (20%) had lymphoma. Overall, 43% of
patients were in remission at transplantation. All
HSCT recipients received peripheral blood as the
stem cell source. Cord blood transplant patients
received an average of 2 logs fewer CD341 cells/kg
than HSCT recipients (Table 1).Neutrophil engraftment
n (%) 55 (85%)
median time,† days (range) 16 (5-57)
Platelet engraftment
n (%) 42 (76%)
median time,‡ days (range) 29 (7%-134)
ALC 1000
n (%) 28 (51%)
median time, days (range) 57 (26%-434)
AML indicates acute myeloid leukemia; MDS, myelodysplastic syndromes;
ALL, acute lymphoblastic leukemia; NHL, non-Hodgkin lymphoma; HD,
Hodgkin disease; CML, chronic myeloid leukemia; MPD, myeloprolifera-
tive disease; CLL, chronic lymphocytic leukemia; FMT, fludarabine, mel-
phalan, and thiotepa conditioning; ATG, antithymocyte globulin; GVHD,
graft-versus-host disease; SCT, stem cell transplant; ALC, absolute lym-
phocyte count; MTX, methotrexate; MMF, mycophenolate mofetil.
*Tacrolimus + MTX 22 patients, tacrolimus + MMF 14 patients, tacroli-
mus alone 1 patient.
†Median 13 days for haploidentical and 21 days for cord blood transplant
recipients.
‡Median 12 days for haploidentical and 35 days for cord blood trans-
plant.ALC Recovery
Overall, ALC recovery to 1000/mL or greater oc-
curred in 51% of patients. Only 5 (28%) of 18 evaluable
patients in T cell–depleted haploidentical transplant
group reached ALC recovery, whereas 23 (68%) of 34
evaluable patients treated with cord blood transplanta-
tion did (P5 .002). The median time to ALC recovery
was 57 days for all patients (range: 26-434 days), with
a median of 62 days for haploidentical transplant and
56 days for cord blood transplant recipients. In 55
patients (85%), the neutrophils engrafted after amedian
of 16 days (range: 8-57 days) and 42 patients (76%) re-
covered platelets to 20,000/mL after amedian time of 29
days (range: 7-134 days). The survival analysis showed
that the type of transplant (cord blood versus haploi-
dentical) had a significant effect on the recovery of the
different blood cells. Although haploidentical trans-
plant patients had faster neutrophil (P \ .0001) and
platelet (P\ .0001) recovery, cord blood transplant pa-
tients recovered ALC sooner than those treated with
haploidentical transplantation (P5 .02). No correlation
between recovery of ALC, engraftment of white blood
cells or platelets, and number of CD341 cells infused
was identified for either cord blood or haploidentical
stem cell transplant recipients. In addition, there was
no evidence that the number of prior chemotherapies
affected lymphocyte recovery; the mean number of
chemotherapies for patients with lymphocyte recovery
at day 100 was 7.8, whereas the mean for patients with-
out lymphocyte recovery at day 100 was 6.6 (P 5 .41,
logistic regression).
A higher proportion of cord blood patients
developed GVHD (22/33, 67%) than haploidentical
patients (7/18, 39%) (P 5 .09, Fisher’s exact test).
GVHD did not seem to impact lymphocyte recoveryin these patients, overall 14/29 (48%) patients with
GVHD had lymphocyte recovery compared with
7/23 (30%) who did not (P 5 .26, Fisher’s exact test).
When this analysis was repeated only for the subset
of 34 cord blood patients, again there was no evidence
of a difference regarding lymphocyte recovery between
patients who developed GVHD (12/22, 54.5%) and
those who did not (6/12, 50%).
Analysis of Outcomes Based on ALC Recovery
Recovery of ALC was evaluated in relationship to
outcomes (survival, disease relapse, and NRM) for all
patients except the 13 who were excluded from analysis
because of primary graft failure or early death. After
a median follow-up of 361 days (range: 62-2220 days)
for the remaining 52 patients, 19 patients (36%) had
disease relapse, 17 (33%) died of nonrelapse-related
causes, and 16 (31%) were alive and relapse-free.
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Thirty-five patients (67%) had died by the end of
follow-up in this study. The median time from trans-
plant to death was 235 days (range: 62-908 days).
Univariate analysis indicated that ALC recovery (P\
.0001) and type of transplant (P5 .02) had a significant
effect on overall survival (OS), whereas multivariate
analysis indicated that, from the factors evaluated,
ALC recovery was the only independent prognostic
factor for OS. Patients without ALC recovery were
10.5 times (95% confidence interval [CI]: 4.4-25.4)
more likely to die than those with ALC recovery
(P\ .0001) (Figure 1).
Relapse
The median time from transplant to relapse was
194 days (range: 55-607 days). In a competing risks
analysis, with NRM considered as a competing event,
univariate analysis of different factors (ALC recovery,
platelet recovery, white blood cell recovery, age, type
of transplant, disease status at transplant, CD341 cell
count/kg) indicated that CD341 cell count/kg
(P\ .01), type of transplant (P5 .02), and disease sta-
tus at transplant (P5 .02) had a significant effect on re-
lapse. Multivariate analysis using regression modeling
in this competing risksmodel indicated that the disease
status at the time of transplantation was the only inde-
pendent prognostic factor for relapse; patients not in
remission were 2.6 times (95% CI: 1.02-6.60) more
likely to have a relapse than those in remission
(P 5 .046). CD341 cell count had a strong trend to-
ward being associated with relapse (P 5 .08), whereas
ALC recovery had no impact on disease relapse.
NRM
The NRM rate was 33% after a median time from
transplant to death of 178 days (range: 64-731 days).
A similar competing risk analysis was performed for
these data, with relapse considered as a competingFigure 1. OS by ALC recovery (n 5 52) (P\.001).event. Univariate analysis revealed that ALC recovery
(P\ .001) and platelet recovery (P5 .005) had a signif-
icant effect on NRM. Multivariate analysis indicated
that, from the factors evaluated, ALC recovery and
platelet recoverywere both independent prognostic fac-
tors for NRM. After adjustment for the type of trans-
plant, patients without ALC recovery were 12.8 times
(95%CI: 4.4-37.1) more likely to haveNRM than those
with ALC recovery (P5 .005) (Figure 2); patients with-
out platelet recovery were 4.0 times (95% CI: 1.7-9.2)
more likely to have NRM than those with platelet
recovery (P 5 .001). The type of transplant was not
an independent prognostic factor for NRM (P 5 .23).
Lack of ALC recovery to 1000/mL by day 60 was
associated with higher NRM rates in cord blood and
haploidentical stemcell transplantation (Figures 3 and4)
(P\ .001 for both types of transplant).Infectious Complications and Lymphocyte
Recovery
The incidence of infectious complications was an-
alyzed for all patients before and after ALC recovery, if
this occurred, and expressed as an incidence rate ratio
(number of infections per number of days analyzed).
Results were similar whether the analysis was done
for the first year posttransplant or overall.
Within the first 365 days, for patients with ALC
recovery, the infection rate before ALC recovery was
significantly higher than that after ALC recovery
(35.5/1,000 patient-days versus 8.6/1,000 patient-
days, P \ .0001). The incidence rate ratio was 4.1
(95% CI: 2.9-6.0). No significant difference in infec-
tion rate was observed between ALC-recovery patients
before their ALC recovery and those who did not have
ALC recovery (35.5/1000 patient-days versus 38.4/
1,000 patient-days, P 5 .6).
Differences in infectious complication rates re-
mained significant for the entire posttransplant period.Figure 2. Cumulative incidence of NRM by ALC recovery within 100
days posttransplant (n 5 52) (P 5 .005).
Figure 3. Cumulative incidence of NRM by ALC recovery in cord
blood transplant patients (n 5 34) (P\.001).
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dence rate before ALC recovery was significantly
higher than that after ALC recovery (35.5/1000
patient-days versus 6.5/1,000 patient-days, P \
.0001). The incidence rate ratio was 5.4 (95% CI:
3.9-7.6). No significant difference was identified in
the infection incidence rate between ALC-recovery
patients before their ALC recovery and those who
did not have ALC recovery (35.5/1,000 patient-days
versus 37.8/1,000 patient-days, P 5 .68) (Table 2).
The great majority of patients without ALC recov-
ery who did not experience graft failure or relapse (8
haploidentical and 10 cord blood transplant recipients)
died of infectious complications. Except 2 patients
with noninfectious cause (both in the cord blood trans-
plant group), all patients died of documented infec-
tion, 7 in the haploidentical and 7 in the cord blood
transplant group, whereas in 2 patients, the organism
was not identified.Figure 4. Cumulative incidence of NRM by ALC recovery in T cell–
depleted haploidentical transplant patients (n 5 18) (P\.001).DISCUSSION
With the current study, we have found that
outcomes of patients treated with cord blood and
T cell–depleted haploidentical transplantation with
lymphocyte recovery by day 60 posttransplant are better
than those without lymphocyte recovery, and showed
that improved survival is because of less NRM related
to infectious complications.
Previous studies demonstrated that early lympho-
cyte recovery in patients with hematologicmalignancies
treated with myeloablative conditioning was associated
with improved outcomes, primarily related to decreased
rate of relapse, in both autologous and allogeneic stem
cell transplant settings [12-23]. Cutoffs of 200, 500, or
1000 cells/mL were used in different analyses for
different types of transplant to evaluate lymphocyte
recovery [12-23]. Because of the variability in ALC
values soon after transplantation, we used ALC
recovery to 1000 cells/mL as a more reliable cutoff for
lymphocyte recovery. In patients with lymphocyte
recovery, the ALC reached 1000/mL at a median of
approximately 2 months posttransplant. This was also
the earliest time point when differences in outcomes
started to become apparent, and these were
increasingly more evident at day 100 posttransplant
and overall, strongly suggesting that the risk of NRM
increases as lymphocyte recovery becomes increasingly
delayed (Figure 5).
Interestingly, studies performed in other types of
transplants appreciated the recovery of lymphocytes in
relation to disease relapse, whereas no association was
demonstrated between ALC recovery and NRM. Our
study identified lack of or delayed ALC recovery as an
important factor closely associated with mortality
from nonrelapse causes. Only 3 (11%) of 28 patients
who recovered ALC after transplant died of nonrelapse
causes compared with 17 (63%) of 27 patients who did
not recover ALC (P\ .0001). Patients who recovered
ALC had a substantial decrease in the infection rate
from 35 to 6 events per 1000 patient-days after ALC
recovery, whereas the group that never recovered
ALC had a rate of 37 events per 1000 patient-days,
which was comparable to the infection rate before
ALC recovery. Taken together, the marked decrease
in the infection rate after ALC recovery and lower mor-
tality in this group suggest that increased protection
form infection may be the reason behind decreased
NRM in the ALC recovery group.
Although similar correlation has been identified
between lymphocyte recovery and outcomes for both
groups, a different pattern of lymphocyte recovery
was observed between the 2 transplant types. The great
majority of patients with T cell–depleted HSCT did
not have ALC recovery, whereas two-thirds of cord
blood transplant recipients did have ALC recovery;
however, delays in lymphocyte recovery of up to
Table 2. Comparison of Infection Rate before and after Lymphocyte Recovery
Incidence Rate Overall
Group ALC Recovery Group
Subgroup Before ALC Recovery After ALC Recovery IRR 95% CI P Value
Infection episodes 74 76
Patient-days 2083 11,657
Rate 35.5 6.5 5.4 (3.9, 7.6) <.0001
Group ALC Recovery Group
Subgroup Before ALC Recovery Non-ALC Recovery
Infection episodes 74 109
Patient-days 2083 2882
Rate 35.5 37.8 0.9 (0.7, 1.3) .68
IRR indicates incidence rate ratio; ALC, absolute lymphocyte count; CI, confidence interval.
1174 Biol Blood Marrow Transplant 17:1169-1175, 2011S. O. Ciurea et al.more than a year were observed in this group. This
finding could explain, at least in part, the prolonged
risk of infectious complications after more than 1
year posttransplant for cord blood transplant recipi-
ents [28]. Similar to other reports, we have found
that a higher number of CD341 cells infused did not
appear to favor faster lymphocyte recovery in these
patients, suggesting that infusion of higher stem cell
doses may not translate into a faster lymphocyte recov-
ery in these patients [12,14].
Although limited by a relatively small number of
patients and its retrospective nature, this study identi-
fied a marked difference in outcomes between patients
who had lymphocyte recovery and those who did not.
Lack of ALC recovery to 1000/mL by day 60 appeared
to be associated with worse outcomes in both cord
blood and T cell–depleted haploidentical stem cell
transplantation. Further studies are needed to identify
subsets of lymphocytes likely to play a greater role in
lymphocyte recovery in these patients. Patients identi-
fied in this fashion could benefit from approachesFigure 5. OS by ALC recovery within 100 days posttransplant (N 5
52) (P\.001).aimed at enhancing immunologic reconstitution
posttransplant. Strategies directed at augmenting
lymphocyte recovery after transplant might improve
outcomes for patients treated with alternative donor
transplantation.ACKNOWLEDGMENTS
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